Capital Analysts LLC’s Atrium Therapeutics RNA Stock Holding History

Capital Analysts LLC’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14	Closed	-$187	–	1668
2026 Q1	$187	Buy	+14	New	+$197	﹤0.01%	1572

Other funds holding RNA

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CRCM LP San Francisco, California $180M AUM 22.87% 1-Year Est. Return

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Capital Analysts LLC's RNA Position: Q2 2026 in Review

Capital Analysts LLC sold out of Atrium Therapeutics (RNA) in Q2 2026, closing a stake of 14 shares — an estimated $187 sold.

Capital Analysts LLC first reported a position in RNA in Q1 2026 and held it in 1 quarter. The position peaked at $187 in Q1 2026. 154 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

Capital Analysts LLC reported no remaining Atrium Therapeutics position as of Q2 2026 after selling out during the quarter.
Capital Analysts LLC sold 14 Atrium Therapeutics shares in Q2 2026, an estimated $187.
Capital Analysts LLC first reported a position in Atrium Therapeutics in Q1 2026 and held it in 1 quarter.
Capital Analysts LLC's Atrium Therapeutics position peaked at $187 in Q1 2026.
154 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.